Byung S. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 132 publications

Real-World Effectiveness and Safety of Deucravacitinib for Plaque Psoriasis: A Multicenter Study in Korea.

Real-World Effectiveness and Safety of Deucravacitinib for Plaque Psoriasis: A Multicenter Study in Korea.

Journal: Annals of dermatology

Published: January 12, 2026

Potential of extracellular vesicle-derived microRNAs as a platform for biomarker discovery in acute lymphoblastic leukemia.

Potential of extracellular vesicle-derived microRNAs as a platform for biomarker discovery in acute lymphoblastic leukemia.

Journal: PloS one

Published: November 03, 2025

Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.

Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.

Journal: Frontiers in immunology

Published: October 24, 2025

Prognostic Factors for Relapse and the Role of Maintenance Therapy in Acute Promyelocytic Leukemia: A Real-World Multicenter Study in Korea.

Prognostic Factors for Relapse and the Role of Maintenance Therapy in Acute Promyelocytic Leukemia: A Real-World Multicenter Study in Korea.

Journal: Cancer research and treatment

Published: August 26, 2025

Assessment tools for peripheral neuropathy in multiple myeloma.

Assessment tools for peripheral neuropathy in multiple myeloma.

Journal: The Korean journal of internal medicine

Published: August 15, 2025

Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide.

Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide.

Journal: Cancer research and treatment

Published: April 17, 2025

Determination of Risk Factors Influencing Psoriatic Arthritis Screening and Evaluation Questionnaire Scores in Palmoplantar Pustulosis: Post Hoc Analysis of EPPPIK Study.

Determination of Risk Factors Influencing Psoriatic Arthritis Screening and Evaluation Questionnaire Scores in Palmoplantar Pustulosis: Post Hoc Analysis of EPPPIK Study.

Journal: Dermatology and therapy

Published: April 08, 2025

Decreased frequency and inflammatory change of FoxP3+ regulatory T cells in immunopathogenesis of human acute graft-versus-host disease.

Decreased frequency and inflammatory change of FoxP3+ regulatory T cells in immunopathogenesis of human acute graft-versus-host disease.

Journal: The Korean journal of internal medicine

Published: January 12, 2025

Disease features, treatments, and burden of palmoplantar pustulosis in Korea: The EPPPIK study.

Disease features, treatments, and burden of palmoplantar pustulosis in Korea: The EPPPIK study.

Journal: The Journal of dermatology

Published: November 26, 2024

Impact of platelet transfusion and bleeding risk stratification in patients with immune thrombocytopenia before procedures.

Impact of platelet transfusion and bleeding risk stratification in patients with immune thrombocytopenia before procedures.

Journal: Scientific reports

Published: August 08, 2024

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment.

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment.

Journal: Scientific reports

Published: August 03, 2024

The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells.

The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells.

Journal: Cancer immunology, immunotherapy : CII

Published: June 10, 2024

Showing 1-12 of 132

Last Updated: 09/26/2026